Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)
A Phase 3 Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Lanadelumab (SHP643) in Japanese Subjects With Hereditary Angioedema
Sponsor: Shire
Listed as NCT04180163, this PHASE3 trial focuses on Hereditary Angioedema (HAE) and remains completed. Sponsored by Shire, it has been updated 13 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Oct 2022 — Dec 2022 [monthly]
Completed PHASE3
-
Sep 2022 — Oct 2022 [monthly]
Completed PHASE3
-
Oct 2021 — Sep 2022 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Apr 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Mar 2020 — Nov 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Dec 2019 — Mar 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shire
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Asahi-shi, Japan , Hiroshima, Japan , Isehara-shi, Japan , Izumo-shi, Japan , Kobe, Japan , Kyoto, Japan , Ogaki-shi, Japan , Soka-shi, Japan , Suita-shi, Japan , Tomakomai-shi, Japan and 2 more locations